New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling

Journal of Biological Chemistry

Volumn 288, Issue 25, 2013, Pages 18335-18344

  Schramm, Christine ^a   Edwards, Michelle A ^a   Krenz, Maike ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC HYPERTROPHY; FOCAL ADHESION KINASE; HYPERTROPHIC CARDIOMYOPATHY; MAMMALIAN TARGET; MULTIPLE LEVELS; NEW APPROACHES; PHARMACOLOGICAL INHIBITION; SIGNALING CASCADES;

BIOCHEMISTRY; BIOLOGY;

PATHOLOGY;

ADENOVIRUS VECTOR; FOCAL ADHESION KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PHPS1; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FIBROBLAST; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HYPERTROPHIC CARDIOMYOPATHY; LEOPARD SYNDROME; MUTATION; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; SH2 DOMAIN; SIGNAL TRANSDUCTION;

AKT; CELL SIGNALING; HEART; LEOPARD SYNDROME; MTOR; PHOSPHATASE; PTPN11; SHP2; SIGNALING; TYROSINE PROTEIN PHOSPHATASE (TYROSINE PHOSPHATASE);

ANIMALS; ANIMALS, NEWBORN; BENZENESULFONATES; BLOTTING, WESTERN; CARDIOMEGALY; CELLS, CULTURED; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; HYDRAZONES; LEOPARD SYNDROME; MICE; MICE, INBRED C57BL; MUTATION; MYOCYTES, CARDIAC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-AKT; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84880076716     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.483800     Document Type: Article

References (45)

1. Marian, A. J. (2010) Hypertrophic cardiomyopathy. From genetics to treatment. Eur. J. Clin. Invest. 40, 360-369
2. Gorlin, R. J., Anderson, R. C., and Blaw, M. (1969) Multiple lentigenes syndrome. Am. J. Dis. Child 117, 652-662
3. Cerrato, F., Pacileo, G., Limongelli, G., Gagliardi, M. G., Santoro, G., Digilio, M. C., Di Salvo, G., Ardorisio, R., Miele, T., and Calabrò, R. (2008) A standard echocardiographic and tissue Doppler study of morphological and functional findings in children with hypertrophic cardiomyopathy compared to those with left ventricular hypertrophy in the setting of Noonan and LEOPARD syndromes. Cardiol. Young 18, 575-580
4. Digilio, M. C., Conti, E., Sarkozy, A., Mingarelli, R., Dottorini, T., Marino, B., Pizzuti, A., and Dallapiccola, B. (2002) Grouping of multiple-lentigines/ LEOPARD and Noonan syndromes on the PTPN11 gene. Am. J. Hum. Genet. 71, 389-394 (Pubitemid 34800254)
5. Legius, E., Schrander-Stumpel, C., Schollen, E., Pulles-Heintzberger, C., Gewillig, M., and Fryns, J. P. (2002) PTPN11 mutations in LEOPARD syndrome. J. Med. Genet. 39, 571-574 (Pubitemid 34864560)
6. Schramm, C., Fine, D. M., Edwards, M. A., Reeb, A. N., and Krenz, M. (2012) The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling. Am. J. Physiol. Heart Circ. Physiol. 302, H231-243
7. Marin, T. M., Keith, K., Davies, B., Conner, D. A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M., Bronson, R., Franchini, K. G., Neel, B. G., and Kontaridis, M. I. (2011) Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 121, 1026-1043
8. Ishida, H., Kogaki, S., Narita, J., Ichimori, H., Nawa, N., Okada, Y., Takahashi, K., and Ozono, K. (2011) LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling. Am. J. Physiol. Heart Circ. Physiol. 301, H1531-1539
9. Edouard, T., Combier, J. P., Nédélec, A., Bel-Vialar, S., Métrich, M., Conte-Auriol, F., Lyonnet, S., Parfait, B., Tauber, M., Salles, J. P., Lezoualc'h, F., Yart, A., and Raynal, P. (2010) Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3β signaling. Mol. Cell Biol. 30, 2498-2507
10. Möllmann, H., Nef, H. M., Kahlert, P., Kostin, S., Möllmann, S., Weber, M., Troidl, C., Hamm, C. W., Holubarsch, C. J., and Elsässer, A. (2008) Negative inotropic effect of rapamycin on isolated human cardiomyocytes. J. Int. Med. Res. 36, 810-814
11. Faienza, M. F., Giordani, L., Ferraris, M., Bona, G., and Cavallo, L. (2009) PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy. What is the link? Pediatr. Cardiol. 30, 1012-1015
12. Takahashi, K., Kogaki, S., Kurotobi, S., Nasuno, S., Ohta, M., Okabe, H., Wada, K., Sakai, N., Taniike, M., and Ozono, K. (2005)Anovel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. Eur. J. Pediatr. 164, 497-500 (Pubitemid 41073816)
13. Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., and Neel, B. G. (2006) PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281, 6785-6792 (Pubitemid 43847615)
14. Nakamura, T., Colbert, M., Krenz, M., Molkentin, J. D., Hahn, H. S., Dorn, G. W., 2nd, and Robbins, J. (2007) Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J. Clin. Invest. 117, 2123-2132 (Pubitemid 47219557)
15. Heidkamp, M. C., Bayer, A. L., Kalina, J. A., Eble, D. M., and Samarel, A. M. (2002) GFP-FRNK disrupts focal adhesions and induces anoikis in neonatal rat ventricular myocytes. Circ. Res. 90, 1282-1289 (Pubitemid 34787410)
16. Krenz, M., Yutzey, K. E., and Robbins, J. (2005) Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. Circ. Res. 97, 813-820 (Pubitemid 41447132)
17. Wang, L., and Proud, C. G. (2002) Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ. Res. 91, 821-829 (Pubitemid 35285080)
18. Heineke, J., and Molkentin, J. D. (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589-600 (Pubitemid 44325350)
19. Peng, X. D., Xu, P. Z., Chen, M. L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W. S., Crawford, S. E., Coleman, K. G., and Hay, N. (2003) Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17, 1352-1365 (Pubitemid 36666005)
20. Yang, Z. Z., Tschopp, O., Di-Poï, N., Bruder, E., Baudry, A., Dümmler, B., Wahli, W., and Hemmings, B. A. (2005) Dosage-dependent effects of Akt1/protein kinase Bα (PKBα) and Akt3/PKBβ on thymus, skin, and cardiovascular and nervous system development in mice. Mol. Cell Biol. 25, 10407-10418 (Pubitemid 41681964)
21. Dummler, B., Tschopp, O., Hynx, D., Yang, Z. Z., Dirnhofer, S., and Hemmings, B. A. (2006) Life with a single isoform of Akt. Mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell Biol. 26, 8042-8051 (Pubitemid 44631003)
22. Dhandapany, P. S., Fabris, F., Tonk, R., Illaste, A., Karakikes, I., Sorourian, M., Sheng, J., Hajjar, R. J., Tartaglia, M., Sobie, E. A., Lebeche, D., and Gelb, B. D. (2011) Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J. Mol. Cell Cardiol. 51, 4-15
23. Oishi, K., Zhang, H., Gault, W. J., Wang, C. J., Tan, C. C., Kim, I. K., Ying, H., Rahman, T., Pica, N., Tartaglia, M., Mlodzik, M., and Gelb, B. D. (2009) Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum. Mol. Genet. 18, 193-201
24. Stewart, R. A., Sanda, T., Widlund, H. R., Zhu, S., Swanson, K. D., Hurley, A. D., Bentires-Alj, M., Fisher, D. E., Kontaridis, M. I., Look, A. T., and Neel, B. G. (2010) Phosphatase-dependent and-independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev. Cell 18, 750-762
25. Fragale, A., Tartaglia, M., Wu, J., and Gelb, B. D. (2004) Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 23, 267-277 (Pubitemid 38337891)
26. Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., Kalidas, K., Patton, M. A., Kucherlapati, R. S., and Gelb, B. D. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465-468 (Pubitemid 34326699)
27. Hellmuth, K., Grosskopf, S., Lum, C. T., Würtele, M., Röder, N., von Kries, J. P., Rosario, M., Rademann, J., and Birchmeier, W. (2008) Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl. Acad. Sci. U.S.A. 105, 7275-7280 (Pubitemid 351754468)
28. Vadali, K., Cai, X., and Schaller, M. D. (2007) Focal adhesion kinase. An essential kinase in the regulation of cardiovascular functions. IUBMB Life 59, 709-716 (Pubitemid 350035589)
29. Xia, H., Nho, R. S., Kahm, J., Kleidon, J., and Henke, C. A. (2004) Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a-1 integrin viability signaling pathway. J. Biol. Chem. 279, 33024-33034 (Pubitemid 39014762)
30. DiMichele, L. A., Hakim, Z. S., Sayers, R. L., Rojas, M., Schwartz, R. J., Mack, C. P., and Taylor, J. M. (2009) Transient expression of FRNK reveals stage-specific requirement for focal adhesion kinase activity in cardiac growth. Circ. Res. 104, 1201-1208
31. Doherty, J. T., Conlon, F. L., Mack, C. P., and Taylor, J. M. (2010) Focal adhesion kinase is essential for cardiac looping and multichamber heart formation. Genesis 48, 492-504
32. Peng, X., Wu, X., Druso, J. E., Wei, H., Park, A. Y., Kraus, M. S., Alcaraz, A., Chen, J., Chien, S., Cerione, R. A., and Guan, J. L. (2008) Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice. Proc. Natl. Acad. Sci. U.S.A. 105, 6638-6643 (Pubitemid 351754559)
33. DeBosch, B., Sambandam, N., Weinheimer, C., Courtois, M., and Muslin, A. J. (2006) Akt2 regulates cardiac metabolism and cardiomyocyte survival. J. Biol. Chem. 281, 32841-32851 (Pubitemid 46036839)
34. DeBosch, B., Treskov, I., Lupu, T. S., Weinheimer, C., Kovacs, A., Courtois, M., and Muslin, A. J. (2006) Akt1 is required for physiological cardiac growth. Circulation 113, 2097-2104
35. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., 3rd, Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., and Birnbaum, M. J. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 292, 1728-1731 (Pubitemid 32506248)
36. Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., and Birnbaum, M. J. (2001) Akt1/PKBβ is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349-38352
37. Chen, L., Sung, S. S., Yip, M. L., Lawrence, H. R., Ren, Y., Guida, W. C., Sebti, S. M., Lawrence, N. J., and Wu, J. (2006) Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol. 70, 562-570 (Pubitemid 44092317)
38. Feng, H., Liu, K. W., Guo, P., Zhang, P., Cheng, T., McNiven, M. A., Johnson, G. R., Hu, B., and Cheng, S. Y. (2012) Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion. Oncogene 31, 2691-2702
39. Jakob, S., Schroeder, P., Lukosz, M., Büchner, N., Spyridopoulos, I., Altschmied, J., and Haendeler, J. (2008) Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J. Biol. Chem. 283, 33155-33161
40. Hanna, N., Montagner, A., Lee, W. H., Miteva, M., Vidal, M., Vidaud, M., Parfait, B., and Raynal, P. (2006) Reduced phosphatase activity of SHP-2 in LEOPARD syndrome. Consequences for PI3K binding on Gab1. FEBS Lett. 580, 2477-2482
41. Karisch, R., Fernandez, M., Taylor, P., Virtanen, C., St-Germain, J. R., Jin, L. L., Harris, I. S., Mori, J., Mak, T. W., Senis, Y. A., Östman, A., Moran, M. F., and Neel, B. G. (2011) Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome." Cell 146, 826-840
42. Agazie, Y. M., and Hayman, M. J. (2003) Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell Biol. 23, 7875-7886 (Pubitemid 37271483)
43. Merritt, R., Hayman, M. J., and Agazie, Y. M. (2006) Mutation of Thr-466 in SHP2 abolishes its phosphatase activity, but provides a new substratetrapping mutant. Biochim. Biophys. Acta 1763, 45-56 (Pubitemid 43208731)
44. Mañes, S., Mira, E., Gómez-Mouton, C., Zhao, Z. J., Lacalle, R. A., and Martínez-A, C. (1999) Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol. Cell Biol. 19, 3125-3135 (Pubitemid 29144557)
45. von Wichert, G., Haimovich, B., Feng, G. S., and Sheetz, M. P. (2003) Force-dependent integrin-cytoskeleton linkage formation requires downregulation of focal complex dynamics by Shp2. EMBO J. 22, 5023-5035 (Pubitemid 37222023)